Drug news
Velcade (Millennium/Janssen Cilag) success in Multiple Myeloma trial
The VISTA trial, compared Velcade, from Millennium and Janssen Cilag, with the established standard of care therapy in 682 patients with previously untreated multiple myeloma. The data showed that patients treated with Velcade, melphalan and prednisone continued to have a statistically significantly longer overall survival than patients treated only with melphalan and prednisone (56.4 versus 43.1 months, p<0.05). the complete data set is to be presented at the american society of hematology meeting. the fda has approved a supplemental new drug application that will include additional overall survival data from the five-year follow up.>
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins